Everything Innovation. Everything New Jersey.
Follow us and stay connected.
Titusville, NJ - While the most recent Ebola epidemic has been in decline, that doesn't mean that vaccine development has to wind down, too. BioNJ Member Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic.
For the full article: http://www.fiercevaccines.com/story/jjs-janssen-strikes-four-year-285m-government-partnership-advance-ebola-vac/2015-09-16?utm_medium=nl&utm_source=internal
Do not miss a single innovative moment and sign up for our newsletter!